eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

4/2020
vol. 12
 
Share:
Share:
more
 
 
abstract:
Original paper

Dosimetric differences between cesium-131 and iodine-125 brachytherapy for the treatment of resected brain metastases

Menachem Z. Yondorf
1, 2
,
Shahdabul Faraz
1
,
Andrew W. Smith
3
,
Albert Sabbas
1
,
Bhupesh Parashar
1
,
Theodore H. Schwartz
4
,
A. Gabriella Wernicke
1, 4

1.
Department of Radiation Oncology, Weill Medical College of Cornell University, New York, USA
2.
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA
3.
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
4.
Department of Neurosurgery, Weill Medical College of Cornell University, New York, NY, US
J Contemp Brachytherapy 2020; 12, 4: 311–316
Online publish date: 2020/08/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
To compare treatment plans and evaluate dosimetric characteristics of permanent cesium-131 (131Cs) vs. iodine-125 (125I) implants used in brain brachytherapy.

Material and methods
Twenty-four patients with 131Cs implants from a prospective phase I/II trial were re-planned with 125I implants. In order to evaluate the volume of brain tissue exposed to radiation therapy (RT), the dose volume histogram was generated for both radioisotopes. To evaluate the dosimetric differences of the two radioisotopes we compared homogeneity (HI) and conformity indices (CI), and dose covering 100% (D100), 90% (D90), 80% (D80), and 50% (D50) of the clinical target volume (CTV).

Results
At the 100%, 90%, 80%, and 50% isodose lines, the 131Cs plans exposed less mean volume of brain tissue than the 125I plans (p < 0.001). The D100, D90, D80, and D50 were smaller for 131Cs (p < 0.001). The HI and CI for 131Cs vs. 125I were 19.71 vs. 29.04 and 1.31 vs. 1.92, respectively (p < 0.001).

Conclusions
Compared to 125I, 131Cs exposed smaller volumes of brain tissue to equivalent doses of radiation and delivered lower radiation doses to equivalent volumes of the CTV. 131Cs exhibited a higher HI, indicating increased uniformity of doses within the CTV. Lastly, 131Cs presented a CI closer to 1, indicating that the total volume receiving the prescription dose was closer to the desired CTV volume. These results suggest that 131Cs is dosimetrically superior to 125I and may explain the reason for the 0% incidence of radiation necrosis (RN) in our previously published prospective study using 131Cs.

keywords:

cesium-131 (131Cs), iodine-125 (125I), brachytherapy, metastases, recurrence, radiation necrosis

 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe